News | September 23, 2013

Facility Recognized for Quality Controls in Platelet Function Analyzer Manufacturing

September 23, 2013 – Aggredyne Inc., has received ISO 13485 certification for its quality control program related to the manufacture of the AggreGuide family of platelet function analyzers.

The ISO 13485 certification covers the design, development, production, sales and service of the AggreGuide instrument and reagent cartridges. The certificate demonstrates that Aggredyne has successfully implemented a quality management system that conforms to the worldwide standard for medical device and diagnostic manufacturing.

The International Organization for Standardization (ISO) is the world's largest developer and publisher of international standards. Aggredyne’s ISO 13485 certificate was awarded by National Quality Assurance (NQA).

"For any medical device manufacturer, but especially for an early-stage company, ISO 13485 certification represents a significant growth milestone," said CEO Edward R. Teitel, M.D. "This designation, along with our previously earned CE mark, recognizes Aggredyne’s commitment to provide our customers with outstanding, high quality products and puts us on a path to increase international sales.”

Aggredyne recently doubled the size of its facility as it prepares for it next growth phase and expansion of its product line. “The larger facility will enable us to meet our growing demand as we advance to our next generation device,” said Andrew Yee, Aggredyne’s vice president of operations and manufacturing.

For more information: www.aggredyne.com


Related Content

News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Videos | Pharmaceuticals

In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based ...

Home September 11, 2023
Home
Videos | Pharmaceuticals

A 3-part video series with Christine E. Seidman, MD, FACC, FAHA In the first of this 3-part “One on One” series, Dr ...

Home August 28, 2023
Home
News | Pharmaceuticals

August 1, 2023 —LEXEO Therapeutics, a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based ...

Home August 01, 2023
Home
News | Pharmaceuticals

July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio ...

Home July 10, 2023
Home
Subscribe Now